Dr. Stock and the team at Signum Biosciences are working to develop the natural product, SIG1012, a minor component of coffee, for clinical application in Alzheimer's disease (AD). SIG1012 restores normal activity of an important cellular protein called PP2A (protein tyrosine phosphatase 2a). PP2A returns tau from a diseased form to its normal state, preventing the accumulation of tau into neurofibrillary tangles seen in the brain of AD patients. Dr. Stock and team have previously provided SIG1012 to mouse models with neurofibrillary tangles and observed a delay in onset of symptoms and decreased mortality. Ongoing AD related studies include the assessment of cognitive and biomarker endpoints in AD mouse models. Together, these studies are designed to efficiently transition into clinical trials and explore cognitive and CSF biomarker endpoints in humans.